Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited

References

• Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896–904.
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64:669–681.
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–1155.
   PubMed Web of Science ®Google Scholar
• Rosen GD, Birkenmeier TM, Raz A, et al. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun. 1989;164:1358–1365.
   PubMed Web of Science ®Google Scholar
• Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353:307–314.
   PubMed Web of Science ®Google Scholar
• Everts B, Wahrborg P, Hedner T. COX-2-specific inhibitors–the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol. 2000;19:331–343.
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006;7:79.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EMEA public statement on the suspension of the marketing authorisation for bextra (valdecoxib) in the European Union. [ cited 2017 Sep 27]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018391.pdf
   Google Scholar
• European Medicines Agency. Questions and answers on the recommendation to withdraw the marketing authorisations for lumiracoxib-containing medicines. [ cited 2017 Sep 27]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/lumiracoxib_107/WC500094235.pdf
   Google Scholar
• Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007;50:470–479.
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000.
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–235.
   PubMedGoogle Scholar
• Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145–182.
   PubMed Web of Science ®Google Scholar
• Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120.
   PubMed Web of Science ®Google Scholar
• Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72:2994–2998.
   PubMed Web of Science ®Google Scholar
• Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663–665.
   PubMed Web of Science ®Google Scholar
• Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977;1:18–20.
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006;5:75–86.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Devchand PR. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol. 2005;145:275–282.
   PubMed Web of Science ®Google Scholar
• Khan KN, Paulson SK, Verburg KM, et al. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int. 2002;61:1210–1219.
   PubMed Web of Science ®Google Scholar
• Norrdin RW, Jee WS, High WB. The role of prostaglandins in bone in vivo. Prostaglandins Leukot Essent Fatty Acids. 1990;41:139–149.
   PubMed Web of Science ®Google Scholar
• Olson DM. The role of prostaglandins in the initiation of parturition. Best Pract Res Clin Obstet Gynaecol. 2003;17:717–730.
   PubMed Web of Science ®Google Scholar
• Alfirevic Z, Keeney E, Dowswell T, et al. Labour induction with prostaglandins: a systematic review and network meta-analysis. BMJ. 2015;350:h217.
   PubMed Web of Science ®Google Scholar
• Brzozowski T, Konturek PC, Konturek SJ, et al. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol. 2005;56 Suppl 5:33–55.
   PubMedGoogle Scholar
• Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med. 2010;61:17–33.
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4–15.
   PubMed Web of Science ®Google Scholar
• Grosser T, Ricciotti E, FitzGerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci. 2017;38:733–748.
   PubMed Web of Science ®Google Scholar
• Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–779.
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S–64S.
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817.
   PubMed Web of Science ®Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Machuga ET, Ozols J. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry. 1983;22:4672–4675.
   PubMed Web of Science ®Google Scholar
• Patrono C, Rocca B. Aspirin and other COX-1 inhibitors. In: Gresele P, Born GVR, Patrono C, et al., editors. Antiplatelet agents. Handbook of experimental pharmacology. 210: Springer Berlin Heidelberg; 2012. p. 137–164.
   Google Scholar
• Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124–132.
   PubMed Web of Science ®Google Scholar
• Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40:1109–1120.
   PubMed Web of Science ®Google Scholar
• Shah A, Woodruff M, Agarwal V, et al. Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis. J Clin Pharmacol. 2001;41:330–339.
   PubMed Web of Science ®Google Scholar
• Evans AM. Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. J Clin Pharmacol. 1996;36:7S–15S.
   PubMed Web of Science ®Google Scholar
• Rao GH, Johnson GG, Reddy KR, et al. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis. 1983;3:383–388.
   PubMedGoogle Scholar
• MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573–574.
   PubMed Web of Science ®Google Scholar
• Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006;80:264–274.
   PubMed Web of Science ®Google Scholar
• Gladding PA, Webster MW, Farrell HB, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008;101:1060–1063.
   PubMed Web of Science ®Google Scholar
• Gengo FM, Rubin L, Robson M, et al. Effects of ibuprofen on the magnitude and duration of aspirin’s inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol. 2008;48:117–122.
   PubMed Web of Science ®Google Scholar
• Anzellotti P, Capone ML, Jeyam A, et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum. 2011;63:850–859.
   PubMed Web of Science ®Google Scholar
• Schuijt MP, Huntjens-Fleuren HW, de Metz M, et al. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol. 2009;157:931–934.
   PubMed Web of Science ®Google Scholar
• Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003;108:1191–1195.
   PubMed Web of Science ®Google Scholar
• Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ. 2003;327:1322–1323.
   PubMedGoogle Scholar
• Fischer LM, Schlienger RG, Matter CM, et al. Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy. 2005;25:503–510.
   PubMed Web of Science ®Google Scholar
• Meek IL, Vonkeman HE, Kasemier J, et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013;69:365–371.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Lamberts M, Olsen AM, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2016;2:108–118.
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96:7563–7568.
   PubMed Web of Science ®Google Scholar
• Dallob A, Hawkey CJ, Greenberg H, et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol. 2003;43:573–585.
   PubMed Web of Science ®Google Scholar
• Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol. 2002;42:1027–1030.
   PubMed Web of Science ®Google Scholar
• Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A. 2001;98:14583–14588.
   PubMed Web of Science ®Google Scholar
• Lee W, Suh JW, Yang HM, et al. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. Korean Circ J. 2010;40:321–327.
   PubMedGoogle Scholar
• Ricciotti E, Yu Y, Grosser T, et al. COX-2, the dominant source of prostacyclin. Proc Natl Acad Sci U S A. 2013;110:E183.
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735–741.
   PubMed Web of Science ®Google Scholar
• McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272–277.
   PubMed Web of Science ®Google Scholar
• Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306:1954–1957.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116:1391–1399.
   PubMed Web of Science ®Google Scholar
• Yu Y, Ricciotti E, Scalia R, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012;4:132ra54.
   PubMed Web of Science ®Google Scholar
• Tang SY, Monslow J, Todd L, et al. Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice. Circulation. 2014;129:1761–1769.
   PubMed Web of Science ®Google Scholar
• Flavahan NA. Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci. 2007;28:106–110.
   PubMed Web of Science ®Google Scholar
• Kirkby NS, Lundberg MH, Harrington LS, et al. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A. 2012;109:17597–17602.
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Warner TD. Reply to Ricciotti et al.: evidence for vascular COX isoforms. Proc Natl Acad Sci U S A. 2013;110:E184.
   PubMed Web of Science ®Google Scholar
• Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and −2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840–845.
   PubMed Web of Science ®Google Scholar
• Zidar N, Odar K, Glavac D, et al. Cyclooxygenase in normal human tissues–is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med. 2009;13:3753–3763.
   PubMed Web of Science ®Google Scholar
• Bolego C, Buccellati C, Prada A, et al. Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone. Faseb J. 2009;23:605–612.
   PubMed Web of Science ®Google Scholar
• Toniolo A, Buccellati C, Pinna C, et al. Cyclooxygenase-1 and prostacyclin production by endothelial cells in the presence of mild oxidative stress. PLoS One. 2013;8:e56683.
   PubMed Web of Science ®Google Scholar
• Wong E, Huang JQ, Tagari P, et al. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis. 2001;157:393–402.
   PubMed Web of Science ®Google Scholar
• Li S, Liu B, Luo W, et al. Role of cyclooxygenase-1 and −2 in endothelium-dependent contraction of atherosclerotic mouse abdominal aortas. Clin Exp Pharmacol Physiol. 2016;43:67–74.
   PubMed Web of Science ®Google Scholar
• Kirkby NS, Lundberg MH, Wright WR, et al. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One. 2014;9:e98165.
   PubMed Web of Science ®Google Scholar
• Ahmetaj-Shala B, Kirkby NS, Knowles R, et al. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation. 2015;131:633–642.
   PubMed Web of Science ®Google Scholar
• Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Intern Med J. 2006;36:308–319.
   PubMed Web of Science ®Google Scholar
• Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405–409.
   PubMed Web of Science ®Google Scholar
• Title LM, Giddens K, McInerney MM, et al. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1747–1753.
   PubMed Web of Science ®Google Scholar
• Widlansky ME, Price DT, Gokce N, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003;42:310–315.
   PubMed Web of Science ®Google Scholar
• Komhoff M, Grone HJ, Klein T, et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997;272:F460–8.
   PubMed Web of Science ®Google Scholar
• Adegboyega PA, Ololade O. Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. Appl Immunohistochem Mol Morphol. 2004;12:71–74.
   PubMedGoogle Scholar
• Nantel F, Meadows E, Denis D, et al. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett. 1999;457:475–477.
   PubMed Web of Science ®Google Scholar
• Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S37–42.
   PubMed Web of Science ®Google Scholar
• Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002;69(Suppl 1):SI53–8.
   PubMedGoogle Scholar
• Stichtenoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Des. 2000;6:1737–1753.
   PubMed Web of Science ®Google Scholar
• Sica DS, Schoolwerth AC, Gehr TW. Pharmacotherapy in congestive heart failure: COX-2 inhibition: a cautionary note in congestive heart failure. Congest Heart Fail. 2000;6:272–276.
   PubMedGoogle Scholar
• Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999;66:76–84.
   PubMed Web of Science ®Google Scholar
• Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465–1470.
   PubMed Web of Science ®Google Scholar
• Dilger K, Herrlinger C, Peters J, et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol. 2002;42:985–994.
   PubMed Web of Science ®Google Scholar
• Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized controlled trial. Ann Intern Med. 2000;133:1–9.
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Thach C, Lasseter KC, et al. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. J Clin Pharmacol. 2007;47:1521–1531.
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther. 2002;72:50–61.
   PubMed Web of Science ®Google Scholar
• Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 2000;7:159–175.
   PubMedGoogle Scholar
• Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther. 2004;26:70–83.
   PubMed Web of Science ®Google Scholar
• Daniels B, Gertz B, Morrison B, et al. Renal safety profile of rofecoxib. A specific inhibitor of Cox-2, in controlled clinical trials. [Abstract]. Arthritis Rheum. 1999;42:S143.
   Google Scholar
• Whelton A, Lefkowith JL, West CR, et al. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int. 2006;70:1495–1502.
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Verheugt FW, Ruland S, et al. A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen. J Clin Hypertens (Greenwich). 2008;10:592–602.
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364:675–684.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368:1771–1781.
   PubMed Web of Science ®Google Scholar
• Krum H, Swergold G, Curtis SP, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009;27:886–893.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296:1619–1632.
   PubMed Web of Science ®Google Scholar
• Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009;27:2332–2341.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, Bolognese JA, et al. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J. 2006;152:237–245.
   PubMed Web of Science ®Google Scholar
• Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2–specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85–95.
   PubMedGoogle Scholar
• Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959–963.
   PubMed Web of Science ®Google Scholar
• Sowers JR, White WB, Pitt B, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:161–168.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539–546.
   PubMed Web of Science ®Google Scholar
• Clement DL, De Buyzere ML, de Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–2415.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–1080.
   PubMed Web of Science ®Google Scholar
• Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895.
   PubMed Web of Science ®Google Scholar
• Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952.
   PubMed Web of Science ®Google Scholar
• ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1:e33.
   PubMedGoogle Scholar
• Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372:1756–1764.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028–1035.
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009;2:310–321.
   PubMed Web of Science ®Google Scholar
• Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125:1481–1492.
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–1091.
   PubMed Web of Science ®Google Scholar
• Yang HM, Kim HS, Park KW, et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation. 2004;110:301–308.
   PubMed Web of Science ®Google Scholar
• Koo BK, Kim YS, Park KW, et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet. 2007;370:567–574.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Oh IY, Chung JW, et al. Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina. Eur Heart J. 2012;33:2653–2661.
   PubMed Web of Science ®Google Scholar
• Chung JW, Yang HM, Park KW, et al. Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial. Circ Cardiovasc Interv. 2010;3:243–248.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343: 1520–1528. 2 p following 8.
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–1255.
   PubMed Web of Science ®Google Scholar
• White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002;89:425–430.
   PubMed Web of Science ®Google Scholar
• Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002;324:1287–1288.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. PRAC recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors. [ cited 2017 Sep 27]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144451.pdf
   Google Scholar
• Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634–1642.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302–1308.
   PubMed Web of Science ®Google Scholar
• Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157:606–612.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375:2519–2529.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA. Imprecision: limitations to interpretation of a large randomized clinical trial. Circulation. 2017;135:113–115.
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT. Therapy: cardiovascular safety of celecoxib, naproxen and ibuprofen. Nat Rev Rheumatol. 2017;13:136–138.
   PubMed Web of Science ®Google Scholar
• Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017;38(44):3282–3292.
   Web of Science ®Google Scholar
• Hirayama A, Tanahashi N, Daida H, et al. Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. Circ J. 2014;78:194–205.
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Hawkey CJ, Ford I, et al. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur Heart J. 2017;38:1843–1850.
   PubMed Web of Science ®Google Scholar
• Signorello LB, McLaughlin JK, Lipworth L, et al. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9:199–205.
   PubMedGoogle Scholar
• Lapi F, Piccinni C, Simonetti M, et al. Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Intern Emerg Med. 2016;11:49–59.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098.
   PubMed Web of Science ®Google Scholar
• Salvo F, Antoniazzi S, Duong M, et al. Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2014;13:573–585.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf. 2011;20:1225–1236.
   PubMed Web of Science ®Google Scholar
• Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909.
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165:978–984.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Castellsague J, Stang MR, et al. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009;18:1016–1025.
   PubMed Web of Science ®Google Scholar
• Shau WY, Chen HC, Chen ST, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan’s National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord. 2012;12:4.
   PubMed Web of Science ®Google Scholar
• Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906–2913.
   PubMed Web of Science ®Google Scholar
• Brophy JM, Levesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007;93:189–194.
   PubMed Web of Science ®Google Scholar
• Sorensen R, Abildstrom SZ, Torp-Pedersen C, et al. Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction. J Cardiovasc Nurs. 2008;23:14–19.
   PubMed Web of Science ®Google Scholar
• Olsen AM, Fosbol EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation. 2012;126:1955–1963.
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313:805–814.
   PubMed Web of Science ®Google Scholar
• Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751–1756.
   PubMed Web of Science ®Google Scholar
• Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354:i4857.
   PubMed Web of Science ®Google Scholar
• Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005;330:1370.
   PubMed Web of Science ®Google Scholar
• Hudson M, Rahme E, Richard H, et al. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum. 2007;57:516–523.
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169:141–149.
   PubMed Web of Science ®Google Scholar
• Chou CI, Shih CJ, Chen YT, et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury. Medicine (Baltimore). 2016 Mar; 95(9):e2645.
   PubMed Web of Science ®Google Scholar
• Lafrance JP, Miller DR. Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol Drug Saf. 2009;18:923–931.
   PubMed Web of Science ®Google Scholar
• Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164:881–889.
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC, Waikar SS, Mogun H, et al. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med. 2008;121:1092–1098.
   PubMed Web of Science ®Google Scholar